Research map: Bridging the Gap in Lung Cancer: Novel Biomarkers, Metabolic Drivers, and Advanced Therapeutics from Bench to Bedside

Back to the article

Papers in this map

  1. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer · Martin Reck · 2016 · 10309 citations · Cited by this paper
  2. Lipoprotein(a) as a Cardiovascular Risk Factor: Clinical Significance and Therapeutic Perspectives · 2026 · Related
  3. Lung cancer immunotherapy: progress, pitfalls, and promises · Aritraa Lahiri · 2023 · 1104 citations · Cited by this paper
  4. Advancing Human Placental Modeling Through Stem-Cell-Derived Trophoblast Organoids and Reprogramming Innovations · 2026 · Related
  5. Small-cell lung cancer: what we know, what we need to know and the path forward · Adi F. Gazdar · 2017 · 950 citations · Cited by this paper
  6. The Role of Endothelial–Mesenchymal Transition (EndMT) in Aneurysm Formation · 2026 · Related
  7. Non-small-cell lung cancer · Lizza E.L. Hendriks · 2024 · 548 citations · Cited by this paper
  8. Ectoine Inhibits IL-1β-Induced Inflammation by Suppressing the NF-κB Pathway in Chondrocytes and Alleviates Osteoarthritis in a Rat Model · 2026 · Related
  9. Cancer Vaccine Therapeutics: Limitations and Effectiveness—A Literature Review · Mariusz Kaczmarek · 2023 · 238 citations · Cited by this paper
  10. Differential Protective Actions of Dulaglutide and Dexamethasone in Methotrexate Induced Pulmonary Fibrosis: Relationship with AMPK and Beclin-1 Levels · 2026 · Related
  11. Emerging strategies to overcome resistance to third-generation EGFR inhibitors · Kunyu Shi · 2022 · 177 citations · Cited by this paper
  12. Evolving Landscape of Systemic Therapy for Hepatocellular Carcinoma: From Targeted Therapy and Combination Strategies to Emerging Therapies · 2026 · Related
  13. First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study · Siow Ming Lee · 2023 · 169 citations · Cited by this paper
  14. Evaluation of Early and Delayed Meloxicam Treatment Against Regulated Cell Death Pathways and ERK1/2 Phosphorylation in a Rat Model of Renal Ischemia–Reperfusion Injury · 2026 · Related
  15. mRNA delivery systems for cancer immunotherapy: Lipid nanoparticles and beyond · Mariona Estapé Sentí · 2024 · 105 citations · Cited by this paper
  16. Overcoming mTOR Inhibitor Resistance: From Biological Basis to Therapeutic Strategies · 2026 · Related
  17. SLC1A3 contributes to L‐asparaginase resistance in solid tumors · Jianhui Sun · 2019 · 73 citations · Cited by this paper
  18. Region-Specific Proteomic Profiles of Extracellular Vesicles (EVs) Derived from Human Macular and Peripheral RPE-Choroid Explants · 2026 · Related
  19. First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study) · R. Descourt · 2023 · 29 citations · Cited by this paper
  20. Real-world clinical outcomes of first-generation and second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large cohort of European non-small-cell lung cancer patients · Adam Płużański · 2020 · 28 citations · Cited by this paper
  21. First-line immune-checkpoint inhibitor plus chemotherapy versus chemotherapy alone for extensive-stage small-cell lung cancer: a meta-analysis · Thierry Landre · 2020 · 25 citations · Cited by this paper
  22. A Propensity-Matched Analysis of Outcomes of Patients with Clinical Stage I Non–Small Cell Lung Cancer Treated surgically or with stereotactic radiotherapy: A Meta-Analysis · Shiwang Wen · 2017 · 23 citations · Cited by this paper
  23. To Biopsy or Not to Biopsy?: A Matched Cohort Analysis of Early-Stage Lung Cancer Treated with Stereotactic Radiation with or Without Histologic Confirmation · Antoine Dautruche · 2020 · 23 citations · Cited by this paper
  24. mRNA Vaccines in Modern Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)—A Comprehensive Literature Review with Focus on Current Clinical Trials · Jacek Kabut · 2025 · 10 citations · Cited by this paper
  25. Real-World Outcomes of First-Line Pembrolizumab Monotherapy in Metastatic NSCLC with High PD-L1 Expression (TPS ≥ 50%): A Multicenter Study from Serbia · Filip Marković · 2025 · 9 citations · Cited by this paper
  26. First-line pembrolizumab in patients with advanced non-small cell lung cancer and high PD-L1 expression: real-world data from a Spanish multicenter study · A. Piedra · 2024 · 7 citations · Cited by this paper
  27. Asparagine synthetase (ASNS) Drives Tumorigenicity in Small Cell Lung Cancer · Minho Jeong · 2025 · 2 citations · Cited by this paper
  28. Proteomic Profiling Reveals TPR and FGA as Predictive Serum Biomarkers of Relapse to First- and Second-Generation EGFR-TKIs in Advanced Lung Adenocarcinoma · Pritsana Raungrut · 2025 · 1 citation · Cited by this paper
  29. The Effectiveness of SBRT for Solitary or Synchronous Multiple Pulmonary Nodules Suspicious of Early-Stage Lung Cancer Without Pathological Confirmation · Emese Csiki · 2025 · 1 citation · Cited by this paper
  30. Untitled · Cited by this paper
  31. Untitled · Cited by this paper
  32. Untitled · Cited by this paper

Source: OpenAlex (CC0)